Clinical Trials
59 trialsTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response
University Hospital Dubrava
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
IoN
University College, London
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
Taichung Veterans General Hospital
A Study of Optical Imaging With Light From Radiotracers in Cancer Patients
Memorial Sloan Kettering Cancer Center
LIBRETTO-321
Eli Lilly and Company
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Mortality Benefit of Ultrasound for Thyroid Nodules Identified With PET Imaging: Non-Inferiority Emulated Target Trial
Brigham and Women's Hospital
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
M.D. Anderson Cancer Center
LIBRETTO-001
Eli Lilly and Company
JPMS-DTC
Bayer
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
Providence Health & Services
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
National Taiwan University Hospital
Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer
National Taiwan University Hospital
iPRIME
University of Chicago
ESTIMABL3
Gustave Roussy, Cancer Campus, Grand Paris
SEACRAFT-1
Erasca, Inc.
Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors
South Egypt Cancer Institute
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer
The Cleveland Clinic
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
LIBRETTO-121
Eli Lilly and Company
Ultrasound Large-scale Model in Thyroid Field: A Multi-center Study on Medical-Engineering Integration
Second Affiliated Hospital of Nanchang University
Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer
University Health Network, Toronto
AS-PTC
University Health Network, Toronto
Laser Ablation of Papillary Thyroid Microcarcinoma
Memorial Sloan Kettering Cancer Center
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Exelixis
PREDICYTHY
Institut du Cancer de Montpellier - Val d'Aurelle
KEYNOTE 158
Merck Sharp & Dohme LLC
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Dana-Farber Cancer Institute
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Eli Lilly and Company
EXAMINER
Exelixis
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Differentiation of Benign From Malignant Thyroid Nodules Using Diffuse Reflectance Spectroscopy
Imperial College London
Measuring Patient Expectations for Thyroid Surgery
Memorial Sloan Kettering Cancer Center
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Memorial Sloan Kettering Cancer Center
RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
AMPLIFY
University of Alabama at Birmingham
Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer
Memorial Sloan Kettering Cancer Center